A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma

Journal of the American Academy of Dermatology

Volumn 57, Issue 4, 2007, Pages 616-621

  Eigentler, Thomas K ^a   Kamin, Anne ^a   Weide, Benjamin M ^a   Breuninger, Helmut ^a   Caroli, Ulrich M ^a   Möhrle, Matthias ^a   Radny, Peter ^a,b   Garbe, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CARCINOMA; SKIN DISEASE; SKIN EDEMA; SKIN EXFOLIATION; SKIN INDURATION; SKIN ULCER; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG ADMINISTRATION SCHEDULE; EMOLLIENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 34548531036     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.05.022     Document Type: Article

References (12)

1. Weinstock M.A. Controversies in the public health approach to keratinocyte carcinomas. Br J Dermatol 154 Suppl 1 (2006) 3-4
2. Rubin A.I., Chen E.H., and Ratner D. Basal-cell carcinoma. N Engl J Med 353 (2005) 2262-2269
3. Stanley M.A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27 (2002) 571-577
4. Beutner K.R., Geisse J.K., Helman D., Fox T.L., Ginkel A., and Owens M.L. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 41 (1999) 1002-1007
5. Geisse J., Caro I., Lindholm J., Golitz L., Stampone P., and Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50 (2004) 722-733
6. Geisse J.K., Rich P., Pandya A., Gross K., Andres K., Ginkel A., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 47 (2002) 390-398
7. Shumack S., Robinson J., Kossard S., Golitz L., Greenway H., Schroeter A., et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 138 (2002) 1165-1171
8. Sterry W., Ruzicka T., Herrera E., Takwale A., Bichel J., Andres K., et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 147 (2002) 1227-1236
9. Sexton M., Jones D.B., and Maloney M.E. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 23 (1990) 1118-1126
10. Breuninger H., and Schaumburg-Lever G. Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs' technique. J Pathol 154 (1988) 167-171
11. Huber A., Huber J.D., Skinner Jr. R.B., Kuwahara R.T., Haque R., and Amonette R.A. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 30 (2004) 429-430
12. Boulinguez S., Grison-Tabone C., Lamant L., Valmary S., Viraben R., Bonnetblanc J.M., et al. Histological evolution of recurrent basal cell carcinoma and therapeutic implications for incompletely excised lesions. Br J Dermatol 151 (2004) 623-626